Nicotinic acid benzylamide is a derivative of nicotinic acid, a vitamin B3 analog, known for its potential therapeutic effects. It has been explored for its pharmacological activity in several areas, including its ability to act as a nicotinic acetylcholine receptor (nAChR) agonist. This compound is synthesized through a reaction involving nicotinic acid and benzylamine. Research indicates that nicotinic acid benzylamide can exert various effects, including anti-inflammatory, analgesic, and neuroprotective actions. Its importance lies in its potential application for treating neurological disorders like Alzheimer's disease and Parkinson's disease. Studies have shown that nicotinic acid benzylamide can improve cognitive function and protect neurons from damage. The compound is being investigated for its ability to modulate nAChR activity, which plays a crucial role in memory, learning, and neuronal signaling.'
nicotinic acid benzylamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 98499 |
| CHEMBL ID | 1739820 |
| SCHEMBL ID | 354041 |
| MeSH ID | M0465515 |
| Synonym |
|---|
| HMS1749G04 |
| AKOS002167603 |
| nsc59992 |
| nsc-59992 |
| n-benzylnicotinamide |
| 3-pyridinecarboxamide, n-(phenylmethyl)- |
| 2503-55-1 |
| nicotinamide, n-benzyl- |
| CBDIVE_012405 |
| OPREA1_664249 |
| n-benzylpyridine-3-carboxamide |
| STK949027 |
| 1322-50-5 |
| nicotinic acid benzylamide |
| unii-hf1w0213qp |
| hf1w0213qp , |
| nsc 59992 |
| einecs 219-705-1 |
| benzyl nicotinamide |
| SCHEMBL354041 |
| DTXSID0062476 |
| CHEMBL1739820 |
| 3-pyridinecarboxamide,n-(phenylmethyl)- |
| Z27749516 |
| Q27279899 |
| 3-pyridinecarboxamide, ar-(phenylmethyl)- (9ci) |
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate time-course and dose-response relationships of nicotinic acid benzylamide (Nic-BZA) with regard to its anticonvulsant activity in the maximal electroshock (MES)-induced seizures and acute neurotoxic effects in terms of motor coordination impairment in the chimney test in mice." | ( Anticonvulsant and acute neurotoxic characteristics of nicotinic acid benzylamide: a preclinical study. Czuczwar, SJ; Paruszewski, R; Swiader, MJ; Turski, WA; Łuszczki, JJ, ) | 0.6 |
| " The evaluation of the side effects present shortly after dosing in the rotarod test has revealed neurotoxicity of Nic-BZA with experimentally determined TD50 value of 188." | ( Protective action of nicotinic acid benzylamide in a variety of chemically-induced seizures in mice. Paruszewski, R; Świąder, K; Świąder, MJ; Turski, WA; Łuszczki, JJ, 2016) | 0.75 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||